Your session is about to expire
← Back to Search
This trial will study how well a medication works in treating ADHD patients, and will also look at how different genetic variants may affect the medication's efficacy.
- Attention Deficit Hyperactivity Disorder (ADHD)
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2020 Phase 4 trial • 267 Patients • NCT02039908
Awards & Highlights
Find a Location
Who is running the clinical trial?
- The study is looking for young people between 6 and 26 years old who have been diagnosed with ADHD as their main health issue.You were not diagnosed with ADHD as your main condition.Children and young adults between the ages of 6 and 26 who have been diagnosed with ADHD as their main health concern.You currently smoke or are pregnant.
- Group 1: Methylphenidate
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Have any other research projects explored the use of Methylphenidate?
"Methylphenidate initially received scientific attention in 2002 at PRODAH and the Hospital de Clínicas de Porto Alegre. To date, 206 studies have been completed on this medication with 29 more trials still actively recruiting participants. Many of these are located within New York City."
How many human participants are involved in this experiment?
"This trial necessitates the inclusion of 500 participants that meet certain criteria. Participants can register to partake in this clinical study at multiple sites, such as Icahn School of Medicine at Mount Sinai (New York) and University of Florida (Gainesville)."
Could I be a participant in this ongoing research?
"This study seeks to enrol 500 children and young adults between the ages of 6 and 26 with a primary diagnosis of ADHD. Other criteria for inclusion involve having previously participated in MPH trials, allowing them to be invited back for more extensive pharmacokinetic testing."
Are there any open slots available for participation in this investigation?
"Affirmative. Information published on clinicaltrials.gov indicates that this medical experiment is currently recruiting patients. It has been available since March 4th 2018 and was most recently updated on April 5th 2022, with the goal of achieving 500 participants across four sites."
Does this experiment seek to enroll participants above the age of 35?
"According to the study's eligibility prerequisites, participants must be between 6 and 26 years old."
Has the FDA sanctioned Methylphenidate for therapeutic use?
"The safety of Methylphenidate is rated highly due to its Phase 4 status, giving it a score of 3. This implies that the medication has been approved for use in clinical settings."
Are there any establishments in North America that are currently administering this research?
"Patients who are interested in this clinical trial can receive treatment at Icahn School of Medicine at Mount Sinai (New York, New York), University of Florida (Gainesville, Florida), Cincinnati Children's Hospital Medical Center (Cincinnati, Ohio) and 4 additional medical sites."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends